Results 71 to 80 of about 5,389 (188)

Tirzepatide in Metabolically Dysfunctional‐Associated Steatohepatitis (MASH): A Bibliometric and Evidence‐Based Review

open access: yesJournal of Diabetes Research, Volume 2026, Issue 1, 2026.
Purpose Metabolically‐dysfunction‐associated steatohepatitis (MASH) is the progressive form of metabolic dysfunction‐associated steatotic liver disease (MASLD) and is strongly linked to obesity and type 2 diabetes mellitus (T2D). Tirzepatide, a dual glucose‐dependent insulinotropic polypeptide (GIP)/glucagon‐like peptide‐1 (GLP‐1) receptor agonist, has
Ileana Pantea   +2 more
wiley   +1 more source

The Role of physical activity and nutrition in the sarcopenia of cirrhosis.

open access: yes, 2016
The aim of this review is to understand how physical activity and nutrition are involved in the improvement of sarcopenia in patients affected by liver cirrhosis.
Aiello, FC   +3 more
core   +1 more source

Expression of Antiangiogenic Prolactin Fragments in the Placentas of Women with Pregnancy Induced Hypertension [PDF]

open access: yes, 2010
It has been reported that prolactin (PRL) is cleaved to 14 or 16 kDa fragments by cathepsin D in vitro and in vivo, and that such fragments exhibit antiangiogenic and proapoptotic properties.
Akahori, Yoichiro   +4 more
core   +1 more source

Abnormal Global Longitudinal Strain Is Associated With Mortality and Waitlist Decompensation in Children With Biliary Atresia Listed for Liver Transplantation

open access: yesLiver International Communications, Volume 6, Issue 4, December 2025.
ABSTRACT Cirrhotic cardiomyopathy (CCM) is prevalent in children with end‐stage liver disease and associated with adverse peri‐transplant outcomes. CCM in children remains poorly characterised and current definitions are restricted to derangements in left ventricular size and mass.
Manpreet K. Virk   +12 more
wiley   +1 more source

Systolic and diastolic impairment in cirrhotic cardiomyopathy: insights from a cross-sectional study

open access: yesEgyptian Liver Journal
Background Cirrhotic cardiomyopathy, an intricate and multifaceted complication of end-stage liver disease, manifests as systolic and diastolic dysfunction in patients without previously diagnosed cardiac disease.
Hala Mansoor   +7 more
doaj   +1 more source

Cardiovascular dysfunction and liver transplantation [PDF]

open access: yesKorean Journal of Anesthesiology, 2018
Cardiovascular complications have emerged as the leading cause of death after liver transplantation, particularly among those with advanced liver cirrhosis.
Hye-Mee Kwon, Gyu-Sam Hwang
doaj   +1 more source

PRMT1 in Health and Disease: Emerging Perspectives From Molecular Mechanisms to Therapeutic Strategies

open access: yesMedComm, Volume 6, Issue 12, December 2025.
Protein arginine methyltransferase 1 (PRMT1) is a pivotal enzyme that catalyzes the asymmetric dimethylation of arginine residues, thereby functioning as a critical epigenetic regulator of diverse biological processes such as gene expression, RNA splicing, and DNA repair.
Yanqun Luo   +4 more
wiley   +1 more source

Exercise Training Attenuates Cirrhotic Cardiomyopathy

open access: yesJournal of Cardiovascular Translational Research, 2020
Cirrhotic cardiomyopathy is a condition where liver cirrhosis is associated with cardiac dysfunction. Triggers and blockers of cirrhotic cardiomyopathy are poorly understood, which might compromise the prognosis of chronic liver disease patients. We tested whether exercise training would reduce liver damage induced by thioacetamide and prevent liver ...
de Souza, Sérgio Luiz Borges   +9 more
openaire   +4 more sources

Bile duct-ligated mice exhibit multiple phenotypic similarities to acute decompensation patients despite histological differences [PDF]

open access: yes, 2015
DWG is a Wellcome Trust senior research fellow and support for work presented here was provided by the Wellcome ...
Acevedo   +27 more
core   +2 more sources

Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome‐Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies

open access: yesAlimentary Pharmacology &Therapeutics, Volume 62, Issue 11-12, Page 1192-1201, December 2025.
In a pooled analysis, bradycardia was observed in 6% of terlipressin‐treated patients but rarely required a dose interruption or reduction. Arrhythmia serious adverse event incidences were low and similar in both treatment groups. Routine intensive cardiac monitoring for the detection of arrhythmias may not be necessary during terlipressin ...
Jasmohan S. Bajaj   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy